Ascend Advanced Therapies, an end-to-end gene therapy development partner, has added two new members to its Executive Team. Scott Broughton has assumed the role of Chief Commercial Officer. Michael Pinaud has joined as Senior Vice President of Business Operations.   These hires are both critical to the rapid evolution of Ascend as a gene to GMP contract development and manufacturing (CDMO).    Mike Stella, CEO of Ascend explained, “We have built Ascend drawing on experience in early AAV disc...